PMID- 32565935
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul
TI  - Ubiquitin-specific peptidase 17 promotes cisplatin resistance via PI3K/AKT 
      activation in non-small cell lung cancer.
PG  - 67-74
LID - 10.3892/ol.2020.11568 [doi]
AB  - The suppression of ubiquitin-specific peptidase 17 (USP17) has previously been 
      found to result in reduced tumorigenesis and invasion of non-small cell lung 
      cancer (NSCLC) cells. However, the functions and underlying mechanisms of USP17 
      in NSCLC progression remain unclear. In the present study, cisplatin treatment 
      was found to upregulate USP17 expression in a dose-dependent manner. Furthermore, 
      USP17-overexpressing (USP17-OE) NSCLC A549 and H1299 cells were generated for 
      mechanistic studies. The results from the Cell Counting Kit-8 assay revealed 
      increased cell proliferation in USP17-OE cells compared with that of control 
      cells. Moreover, the viability of USP17-OE cells was significantly higher than 
      that of the control cells, when treated with cisplatin. The results of the 
      biochemical studies demonstrated enhanced PI3K and AKT phosphorylation in 
      USP17-OE NSCLC cells, whereas USP17-knockdown decreased these levels of 
      phosphorylation. By contrast, an AKT inhibitor abolished the USP17-mediated 
      enhancement of proliferation. Moreover, suppression of USP17 or the combination 
      of the AKT inhibitor and cisplatin significantly reduced cell viability. Overall, 
      the results of the present study suggest that PI3K/AKT activation is the 
      underlying mechanism of USP17-mediated cisplatin resistance in NSCLC.
CI  - Copyright: (c) Zhang et al.
FAU - Zhang, Shengchao
AU  - Zhang S
AD  - Department of Thoracic Surgery, Qingpu Branch Zhongshan Hospital, Fudan 
      University, Shanghai 201700, P.R. China.
FAU - Xu, Zhenglang
AU  - Xu Z
AD  - Department of Thoracic Surgery, Qingpu Branch Zhongshan Hospital, Fudan 
      University, Shanghai 201700, P.R. China.
FAU - Yuan, Jun
AU  - Yuan J
AD  - Department of Thoracic Surgery, Qingpu Branch Zhongshan Hospital, Fudan 
      University, Shanghai 201700, P.R. China.
FAU - Chen, Hao
AU  - Chen H
AD  - Department of Thoracic Surgery, Qingpu Branch Zhongshan Hospital, Fudan 
      University, Shanghai 201700, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7286115
OTO - NOTNLM
OT  - AKT inhibitor
OT  - cisplatin
OT  - non-small cell lung cancer
OT  - ubiquitin-specific peptidase 17
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
PMCR- 2020/04/23
CRDT- 2020/06/23 06:00
PHST- 2018/11/08 00:00 [received]
PHST- 2019/11/22 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
PHST- 2020/04/23 00:00 [pmc-release]
AID - OL-0-0-11568 [pii]
AID - 10.3892/ol.2020.11568 [doi]
PST - ppublish
SO  - Oncol Lett. 2020 Jul;20(1):67-74. doi: 10.3892/ol.2020.11568. Epub 2020 Apr 23.